Sugi Predict

Sugi Predict / Compounds / SCHEMBL14716612

SCHEMBL14716612

SCHEMBL14716612

Cc1cc(Cc2ccccc2)[nH]c(=O)c1CNC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ EZH2 Q15910 10/20 0.46
▸ EED O75530 4/20 0.44
▸ RBBP4 Q09028 4/20 0.44
▸ SUZ12 Q15022 4/20 0.44
▸ AEBP2 Q6ZN18 4/20 0.44
▸ ADORA1 P30542 1/20 0.43
▸ PARP1 P09874 1/20 0.43
▸ KLKB1 P03952 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ KLK1 P06870 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14760447 0.87 EED (0.44) ALDH1A1KDM4EHPGDHSD17B10EED
SCHEMBL9887613 0.86 KDM4A (0.44) ALDH1A1KDM4EHPGDHSD17B10EZH2
SCHEMBL14734270 0.85 EZH2 (0.41) ALDH1A1KDM4EHPGDHSD17B10EZH2
SCHEMBL2594511 0.80 PARP1 (0.50) ALDH1A1KDM4EADORA1PARP1SMN1; SMN2
Hydrochloric Acid SCHEMBL2594087 0.79 PARP1 (0.49) ALDH1A1KDM4EADORA1PARP1SMN1; SMN2
SCHEMBL15797726 0.79 CYP1A2 (0.44) ALDH1A1KDM4EHPGDHSD17B10PARP1
SCHEMBL14716843 0.78 EED (0.60) ALDH1A1KDM4EHPGDHSD17B10EZH2
SCHEMBL15173371 0.76 EZH2 (0.56) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL9286770 0.76 PARP1 (0.51) ALDH1A1KDM4EHPGDADORA1PARP1
SCHEMBL9277469 0.76 LMNA (0.45) ALDH1A1KDM4EHSD17B10ADORA1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10478426-B2 Enhancer of Zeste Homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2019-11-19 — — US disclosed
US-20180207144-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2018-07-26 — — US disclosed
US-9956210-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-3246027-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER GlaxoSmithKline LLC (US) 2017-11-22 — — EP disclosed
US-9649307-B2 Indoles GLAXOSMITHKLINE LLC (US) 2017-05-16 — — US disclosed
US-20170095461-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE LLC 2017-04-06 — — US disclosed
EP-2755962-B1 AZAINDAZOLES GLAXOSMITHKLINE LLC (US) 2017-03-01 — — EP disclosed
US-9562041-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE LLC (US) 2017-02-07 — — US disclosed
US-20160296518-A1 INDOLES GLAXOSMITHKLINE LLC 2016-10-13 — — US disclosed
EP-2646020-B1 INDOLES GLAXOSMITHKLINE LLC (US) 2016-09-21 — — EP disclosed
EP-2773754-A1 METHOD OF TREATMENT Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-09-10 — — EP disclosed
US-8765792-B2 Indoles GLAXOSMITHKLINE LLC (US) 2014-07-01 — — US disclosed
US-20130345200-A1 INDOLES GLAXOSMITHKLINE LLC (US) 2013-12-26 — — US disclosed
US-20130245016-A1 INDOLES GLAXOSMITHKLINE LLC 2013-09-19 — — US disclosed
US-8536179-B2 Indoles GLAXOSMITHKLINE LLC (US) 2013-09-17 — — US disclosed
WO-2013067302-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2013-05-10 — — WO disclosed
WO-2013067296-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) 2013-05-10 — — WO disclosed
WO-2013067300-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2013-05-10 — — WO disclosed
US-20130053397-A1 INDOLES GLAXOSMITHKLINE LLC 2013-02-28 — — US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245016-A1 INDOLES IDO1, IDO2, INMT ALDH1A1 38/4885KDM4E 1312/4885HPGD 375/4885
US-20130053383-A1 INDAZOLES IDH3A, CYP3A7, IDH3B ALDH1A1 48/4885KDM4E 2573/4885HPGD 257/4885
US-20180207144-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, EZH1, BMI1 ALDH1A1 1092/4885KDM4E 43/4885HPGD 2177/4885
US-20170095461-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, EZH1, BMI1 ALDH1A1 1092/4885KDM4E 43/4885HPGD 2177/4885
US-10478426-B2 Enhancer of Zeste Homolog 2 inhibitors EZH2, EZH1, BMI1 ALDH1A1 1092/4885KDM4E 43/4885HPGD 2177/4885
US-20130345200-A1 INDOLES IDO1, IDO2, INMT ALDH1A1 38/4885KDM4E 1312/4885HPGD 375/4885
US-20130053397-A1 INDOLES IDO1, IDO2, INMT ALDH1A1 45/4885KDM4E 1253/4885HPGD 403/4885
US-20160296518-A1 INDOLES IDO1, IDO2, INMT ALDH1A1 38/4885KDM4E 1312/4885HPGD 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.